Molecular subtypes of breast cancer, do they differ in different age groups among Egyptian female individuals? (retrospective study)

2017 ◽  
Vol 37 (1) ◽  
pp. 160-164
Author(s):  
Bassma El Sabaa ◽  
Haytham Fayed
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Molecular Subtypes ◽  
Age Groups

scholarly journals Prevalence of Molecular Subtypes of Breast Carcinoma and Its Comparison between Two Different Age Groups: A Retrospective Study from a Tertiary Care Center of Northeast India

2021 ◽  
Vol 10 (04) ◽  
pp. 220-224
Author(s):  
Jagannath Dev Sharma ◽  
Sachin Khanna ◽  
Shubhra Ramchandani ◽  
Lopa Mudra Kakoti ◽  
Argha Baruah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Triple Negative ◽  
Molecular Subtypes ◽  
Molecular Subtype ◽  
Age Groups ◽  
Age Group ◽  
Luminal A ◽  
Luminal B ◽  
Her 2

Abstract Objective The aim of the study is to see the prevalence of different molecular subtypes in breast cancer patients among two different age groups: ≤40 years and >40 years. Materials and Methods Retrospective study was conducted from January 2019 to December 2019. We studied 568 cases of breast carcinoma and classified them into four molecular subtypes—luminal A, luminal B, human epidermal growth factor-2 (HER 2), and triple negative. Cases were divided into two different groups: (1) ≤40 years and (2) >40 years. Statistical Analysis was done by using SPSS software version 20.0. Results Out of 568 cases, 151 (26.6%) were ≤40 years of age and 417 (73.4%) were >40 years of age. The most common histological subtype of breast cancer was ductal carcinoma in 548 cases and the most common grade was grade III. Immunohistochemistry was done in 432 patients. In younger age group, the most common molecular subtype was luminal B (31%) followed by triple negative (20%), luminal A (14%), and then HER 2 (5.3%), while in the older age group most common molecular subtype was luminal B (27.8%) followed by triple negative (14%), HER 2 (12.2%), and then luminal A (12%). Conclusion Luminal B is found to be the most common subtype in Northeast Indian women with breast cancer, as compared with other studies in which luminal A was the most common subtype. This could be due to the reason that Ki-67 was not done in most of the other studies.

scholarly journals Prevalence of molecular subtypes of invasive breast cancer: A retrospective study

2015 ◽  
Vol 71 (3) ◽  
pp. 254-258 ◽  
Author(s):  
Nikhilesh Kumar ◽  
Preeti Patni ◽  
A. Agarwal ◽  
M.A. Khan ◽  
Nidhi Parashar
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Invasive Breast Cancer ◽  
Molecular Subtypes

scholarly journals Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study

2012 ◽  
Vol 5 (1) ◽  
Author(s):  
Sanae Bennis ◽  
Fouad Abbass ◽  
Yousra Akasbi ◽  
Kaoutar Znati ◽  
Khalid Amrani Joutei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Invasive Breast Cancer ◽  
Molecular Subtypes ◽  
North East

Real-world hematologic toxicities in patients > 70 versus < 69 with ER positive metastatic breast cancer on CDK 4/6 inhibitors: Single-institution retrospective study.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13039-e13039
Author(s):  
Coral Olazagasti ◽  
Wingsze Liu ◽  
Chung-Shien Lee ◽  
Taylor Decina ◽  
Karalyn Pappas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Retrospective Study ◽  
Bone Metastasis ◽  
Age Groups ◽  
Metastatic Breast ◽  
Hematologic Toxicity ◽  
Single Institution ◽  
Significant Difference ◽  
Er Positive

e13039 Background: Since 2015, CDK4/6 inhibitors (CDKi) have become part of standard of care in the treatment ER-positive, Her2Neu negative of metastatic breast cancer (MBC). Hematologic toxicity from CDKi are common. Pooled analysis of prior randomized trials did not show hematologic toxicity between younger and older adult age groups. We sought to review generalizability of these findings to our community population. Methods: We conducted a retrospective single institution retrospective study on patients who were treated with CDKi from 2015 to 2019. Patients were stratified according to age > 70 years and < 69 years. Data from absolute neutrophil count, hemoglobin and platelet count on Days 1 and 15 of the first 2 cycles were graded for hematologic toxicity according to CTCAE v 5.0. Our primary objective was to assess any difference in grade of hematologic toxicities in the different age groups. Our secondary objective was to analyze the association between hematologic toxicities with the presence or absence of bone metastasis and/or prior chemotherapy exposure. Results: A total of 220 patients were reviewed, 140 were < 69 years and 80 > 70 years. There was no significant effect of time (p = 0.91) with respect to the outcome of hematologic toxicity adjusting for age (p = 0.16). Seventy-seven percent (171/220) of patients had evidence of bone marrow (BM) involvement. There was no significant difference in the grade of any hematologic toxicities over time (p = 0.97) and underlying BM disease (p = 0.20). On the other hand, 50% (111/220) patients had previously received an average of one line of chemotherapy. There was significant positive correlation between lines of therapy and grade of neutropenia (rS= 0.25, p = 0.0028). Overall, the estimated median progression free survival (PFS) was 19.1 months. The median overall survival could not be estimated. Conclusions: Our single institution experience does not show significant hematologic toxicity between patient age groups nor evidence of bone metastasis. However, prior exposure to chemotherapy can have a significant effect in the grade of neutropenia. Our study revealed that there is no difference in PFS according to dosing or age which correlates with current literature.

scholarly journals Breast cancer in south-east Republic of Yemen

2001 ◽  
Vol 7 (06) ◽  
pp. 1012-1016
Author(s):  
G. Abdul Hamid ◽  
M. S. Tayeb ◽  
A. A. Bawazir
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Retrospective Study ◽  
Teaching Hospital ◽  
Ductal Carcinoma ◽  
Age Groups ◽  
Lymph Node Involvement ◽  
Cancer Centre ◽  
Infiltrating Ductal Carcinoma ◽  
Node Involvement

A retrospective study of breast cancer was carried out using the treatment registry of Aden Health Office and archives of Al-Gamhoria Teaching Hospital from January 1989 to December 1996 and the records of patients registered at Aden Cancer Centre from January 1997 to December 1998. The data analysed included age, sex, residence, breast affected and type of cancer. There were 227 patients with breast cancer registered between January 1989 and December 1998; 225 were female and 2 were male. Most of the patients [81.5%] had infiltrating ductal carcinoma. About 90% of the patients had lymph node involvement. The age groups most affected were 30-39 years and 40-49 years.

scholarly journals Molecular Subtypes, Metastatic Pattern and Patient Age in Breast Cancer: An Analysis of Italian Network of Cancer Registries (AIRTUM) Data

2021 ◽  
Vol 10 (24) ◽  
pp. 5873
Author(s):  
Giovanna Tagliabue ◽  
Sabrina Fabiano ◽  
Paolo Contiero ◽  
Giulio Barigelletti ◽  
Maurizio Castelli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Subtypes ◽  
Age Groups ◽  
Cancer Registries ◽  
Receptor Expression ◽  
National Database ◽  
Italian Population ◽  
Patient Age ◽  
Primary Tumors ◽  
Patient Âgé

Breast cancer stage at diagnosis, patient age and molecular tumor subtype influence disease progression. The aim of this study was to analyze the relationships between these factors and survival in breast cancer patients among the Italian population using data from the AIRTUM national database. We enrolled women with primary breast cancer from 17 population-based cancer registries. Patients were subdivided into older (>69 years), middle (50–69 years) and younger age groups (<50 years) and their primary tumors categorized into four molecular subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. There were 8831 patients diagnosed between 2010 and 2012 included. The most represented age group was 50–69 years (41.7%). In 5735 cases the molecular subtype was identified: HER2–/HR+ was the most frequent (66.2%) and HER2+/HR− the least (6.2%). Of the 390 women with metastases at diagnosis, 38% had simultaneous involvement of multiple sites, independent of age and molecular profile. In women with a single metastatic site, bone (20% of cases), liver (11%), lung (7%) and brain (3%) were the most frequent. In the studied age groups with different receptor expression profiles, the tumor metastasized to target organs with differing frequencies, affecting survival. Five-year survival was lowest in women with triple-negative (HER2−/HR–) tumors and women with brain metastases at diagnosis.

scholarly journals Incidence trend for breast cancer among young women in Goiânia, Brazil

2010 ◽  
Vol 128 (2) ◽  
pp. 81-84 ◽  
Author(s):  
Ruffo Freitas-Junior ◽  
Nilceana Maya Aires Freitas ◽  
Maria Paula Curado ◽  
Edesio Martins ◽  
Carleane Maciel Bandeira Silva ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Cancer Registry ◽  
Young Women ◽  
Cancer Incidence ◽  
Poisson Regression ◽  
Breast Cancer Incidence ◽  
Age Groups ◽  
Population Based ◽  
Incidence Trend

CONTEXT AND OBJECTIVE: It has been suggested that there has been a large increase in breast cancer incidence among young women over the last decade. The aim of this study was to describe the incidence of breast cancer among young women up to 39 years of age in Goiânia, between 1988 and 2003, and to compare this with other age groups. DESIGN AND SETTING: Retrospective study using the database of the Population-based Cancer Registry of Goiânia, State of Goiás, Brazil. METHODS: The incidence was calculated according to age groups: up to 39 years, 40 to 59 years and 60 years and over. Average annual percentage changes (AAPCs) were estimated for the different age groups using Poisson regression. RESULTS: Over this period, 3,310 new cases were recorded. The standardized incidence was 2.89/100,000 in 1988 and increased to 6.37/100,000 in 2003 (R² = 0.52) for the group aged up to 39 years (p < 0.003). For the group from 40 to 59 years old, the incidence was 14.39/100,000 in 1988 and 41.70/100,000 in 2003 (R² = 0.85; p < 0.001). For the group aged 60 years and over, it was 17.62/100,000 and 28.49/100,000, respectively (R² = 0.67; p < 0.001). The AAPCs were 5.22%, 5.53% and 4.54% for the age groups up to 39, 40 to 59 and 60 years and over, respectively. CONCLUSIONS: The incidence of breast cancer among young women in Goiânia has been increasing significantly, although this change was similar to the increase in other age groups.

Sign in / Sign up

Export Citation Format

Share Document